The first specific profilactic therapy for migraine

Abstract:

Migraine represents a problem for both individuals and a society. Some patients require prophylactic treatment to reduce the migraine attack frequency and severity. Prophylactic treatment is associated with many challenges - such as low persistence and adherence, cessation of treatment as it is often accompanied with side effects, lack of effect, or contraindications in some patients. Studies have shown that CGRP plays a key role in the migraine pathophysiology. Development of monoclonal CGRP antibodies represents a specific migraine therapy. In contrast to the current therapy, monoclonal antibodies have earlier onset of effect, monthly administration, almost no interactions with other drugs, fewer side effects and no need for titration. Research has proved their good safety profile and their efficacy in prophylaxis of episodic and chronic migraine. Discovery of CGRP monoclonal antibodies has allowed for a long-awaited, specific, efficient and safe migraine prophylactic treatment.

Key words:
CGRP antibodies, migraine, prophylactic treatment